Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
Status:
Terminated
Trial end date:
2021-03-10
Target enrollment:
Participant gender:
Summary
Phase I/II trial in which participants with recurrent glioblastoma will receive a combination
of tumor treating fields(portable device), nivolumab with or without ipilimumab.